Related Experiment Video

Updated: Jul 19, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib

Olwen Hahn1, Walter Stadler

  • 1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Illinois 60637, USA.

Current Opinion in Oncology
|September 22, 2006
PubMed
Abstract

Insights

Sorafenib, an oral multikinase inhibitor, demonstrated increased progression-free survival in metastatic renal cell cancer patients. This finding was confirmed in phase III trials, establishing its role in renal cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Sorafenib is an oral multikinase inhibitor approved for metastatic renal cancer.
  • It targets multiple tyrosine kinases, including VEGFR and PDGFR, and Raf kinase.
  • Investigational use extends to locally advanced renal cancer and other tumor types.

Purpose of the Study:

  • To review the clinical development of sorafenib.
  • To discuss its role in treating renal cancer.
  • To highlight clinical trial design and biomarker development.

Main Methods:

  • Phase II randomized discontinuation trial to assess clinical benefit.
  • Phase III international trial to confirm phase II findings.
  • Review of clinical development and trial methodologies.

Main Results:

  • Sorafenib demonstrated prolonged disease stabilization in early trials.
  • A phase II trial showed increased progression-free survival in metastatic renal cell cancer.
  • Phase III trials confirmed these positive outcomes.

Conclusions:

  • Sorafenib has a significant role in the treatment of renal cancer.
  • Effective clinical trial design and biomarker development are crucial for drug advancement.
  • Further research into sorafenib's application in various cancers is ongoing.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...